Skip to content
Advertisement

FILE - This Jan. 24, 2015, file photo, shows the exterior of AbbVie, in Lake Bluff, Ill. AbbVie is buying Botox maker Allergan in a cash-and-stock deal the drugmakers value at around $63 billion. The maker of the blockbuster immune disorder treatment Humira said Tuesday, June 25, 2019, that it will pay $120.30 in cash and a portion of AbbVie stock for each Allergan share. (AP Photo/Nam Y. Huh, File)

FILE - This Jan. 24, 2015, file photo, shows the exterior of AbbVie, in Lake Bluff, Ill. AbbVie is buying Botox maker Allergan in a cash-and-stock deal the drugmakers value at around $63 billion. The maker of the blockbuster immune disorder treatment Humira said Tuesday, June 25, 2019, that it will pay $120.30 in cash and a portion of AbbVie stock for each Allergan share. (AP Photo/Nam Y. Huh, File)

Featured Photo Galleries